METUPUK are delighted for the approval of Trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults who have received one or more prior anti-HER2 based therapies approved for use through the Cancer Drugs Fund in NHS in England.
If a person has a heart attack, do they get told that they will never have a heart attack again and they are free of heart disease?
METUPUK was over the moon to receive an amazing donation from Hearts & Hope 4 Helen. The cheque was handed over to METUPUK at the Darker Pink exhibition, which is currently in the Michell Library in Glasgow.
METUPUK welcomes the Scottish Medicines Consortium (SMC) decision to accept pembrolizumab (Keytruda, Merck Sharp and Dohme) plus chemotherapy (paclitaxel or nab-paclitaxel) for use on the NHS in Scotland. Pembrolizumab is
METUPUK welcomes the approval of Piqray (alpelisib) plus fulvestrant for the treatment of hormone receptor-positive, HER2-negative, PIK3CA- mutated advanced breast cancer.
Piqray is an exciting new cancer medicine because it is the first targeted treatment option for advanced breast cancer that has a PIK3CA mutation.
METUPUK are delighted that NICE has accepted Trodelvy (sacituzumab govitecan) for routine use on the NHS in England for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior lines of systemic therapies. This follows on from the decision to approve Trodelvy in NHS Scotland in March 2022. Wales and Northern Ireland normally follow decisions by NHS England and we hope that Trodelvy will be made available to every patient who is eligible without delay.
Today we want to honour our friend and MetUpUK member Emma Hillier.
A new campaign in Wales, by MetUpUK member Tassia Haines, aims to draw attention to the fact that Metastatic Breast Cancer (MBC) patients feel that they are being failed by the Welsh Government.
Have you ever wondered what the relationship is like between primary and secondary breast cancer patients when they are talking about cancer?
We’ve put 4 of our MetUpUK members on a zoom call to chat it out – Mary and Laura have secondary cancer and Helen and Emily have had primary breast cancer.
A diagnosis of cancer is a major life event. None of us is immune to the
potential of developing the disease. It doesn’t discriminate by age, gender,
sexual orientation or ethnicity. It can also develop in any part of the body. In
the case of breast cancer, one in seven women will be diagnosed with it
during their lifetime. Approximately 30% of those women will go on to develop secondary breast cancer.
